Navigation Links
MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
Date:5/29/2008

MOUNTAIN VIEW, Calif., May 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Marco F. Rosa to the newly created position of Vice President of Human Resources.

Mr. Rosa brings over 20 years of human resources experience to the Company. Most recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. as Vice President of Worldwide Human Resources, a position he had held since May of 2002. He was an integral part of the senior management team overseeing the company's growth and the commercial launch of several ophthalmology and surgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as Vice President, Human Resources at COR Therapeutics, Inc., building the development and commercial organizations and launching Integrilin(R) in the cardiovascular angioplasty market. Before joining COR, Mr. Rosa held senior human resources and key administrative management positions with ReplayTV, Inc., Genelabs Technologies, Inc., and Sony Electronics Inc. Prior to 1990, Mr. Rosa held similar management positions with the General Electric Company where he started his career in human resources.

"I'm pleased to have Marco join our management team and help to develop the future of the company as we continue our late-stage product development and move toward potential commercialization," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "Marco brings unique company building expertise to our efforts to develop improved therapies for children and adults who suffer from diseases that we believe are not adequately treated by currently available medicines."

In addition to his extensive human resources experience, Mr. Rosa served as a Captain in the BioMedical Corps of the United States Air Force. Mr. Rosa received his B.A. degree in Psychology from St. Michael's College and his M.A. degree in Counseling Psychology from New York University.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
2. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
5. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
6. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
7. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
8. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
9. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
10. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
11. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):